Research Analysts’ Recent Ratings Changes for Twist Bioscience (TWST)

Twist Bioscience (NASDAQ: TWST) has recently received a number of price target changes and ratings updates:

• 6/29/2026 – Twist Bioscience had its price target raised by Guggenheim from $60.00 to $107.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Twist Bioscience had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – Twist Bioscience had its price target raised by Barclays PLC from $65.00 to $95.00. They now have an “overweight” rating on the stock.
• 6/15/2026 – Twist Bioscience had its price target raised by TD Cowen from $68.00 to $89.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Twist Bioscience is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $90.00 price target on the stock.
• 6/15/2026 – Twist Bioscience was given a new $89.00 price target by UBS Group AG.
• 6/15/2026 – Twist Bioscience had its price target raised by TD Cowen from $68.00 to $89.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Twist Bioscience is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $90.00 price target on the stock.
• 6/11/2026 – Twist Bioscience is now covered by Piper Sandler. They set an “overweight” rating and a $85.00 price target on the stock.
• 6/11/2026 – Twist Bioscience is now covered by Piper Sandler. They set an “overweight” rating and a $85.00 price target on the stock.
• 5/22/2026 – Twist Bioscience was given a new $80.00 price target by Leerink Partners.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 291 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the sale, the senior vice president owned 120,414 shares in the company, valued at approximately $10,514,550.48. This trade represents a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 18,880 shares of Twist Bioscience stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total transaction of $1,793,600.00. Following the completion of the transaction, the chief executive officer directly owned 824,039 shares in the company, valued at $78,283,705. This trade represents a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,580 shares of company stock worth $5,169,482 in the last 90 days. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.